GILEAD SCIENCES, INC.
GILD · Biological Products, (No Diagnostic Substances) · 1.24B shares · -0%/yr ↓ buyback · EDGAR filings ↗
Net buyback after stock comp: $234M (gross $1.0B, SBC $766M)
Reference price $123.42 · est. market cap ~$153.2B — last insider sale, 2026-06-15 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
A85Wide-moat HIV/virology franchise with top-decile cash generation and margins, lightly de-risked by a positive Phase 3 readout despite some oncology misses.
Strengths
- Top-decile profitability: FCF 95th pct, net margin 95.9th, operating margin 94.5th, ROA 92.5th, with $9.5B FCF (100th pct)
- Durable HIV moat extended by Biktarvy LOE settlement to 2036 and twice-yearly lenacapavir (Yeztugo) franchise
- ROE ~37% on a large equity base; strong, diversified commercial portfolio
Risks
- Pipeline setbacks: ASCENT-07 missed PFS, STAR-221 discontinued, HBV combos failed, BIC/LEN clinical hold
- Elevated leverage (debt/equity 83rd pct) and below-median liquidity (current ratio 23.5th pct)
- Oncology/inflammation build-out still unproven relative to virology core
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Revenue declineRevenue -12.2% YoY
- Notable holderHeld by 6 notable fund(s): FMR LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC +3 more (as of 2026-03-31)
- AccumulatingInstitutional holders rose 27→31 QoQ (2025-12-31→2026-03-31)
- Insider sellingInsider selling — 33 open-market sale(s) by 4 insider(s) (cluster of 4 insiders, ~$53M, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2026-08 — PHASE2 · Head and Neck Squamous Cell Carcinoma
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
78.8%
Operating margin
34.0%
Net margin
28.9%
Return on equity
37.5%
Return on assets
14.4%
ROIC
16.6%
Revenue growth (QoQ)
-12.2%
Debt / equity
1.1×
Current ratio
1.6×
Free cash flow
$9.5B
Tangible book value
-$2.6B
Stock comp / revenue
3.0%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-15 | Mercier Johanna | Sell | 1.5K | $123.42 |
| 2026-06-15 | Mercier Johanna | Sell | 450 | $125.40 |
| 2026-06-15 | Mercier Johanna | Sell | 1.1K | $124.00 |
| 2026-06-15 | Dickinson Andrew D | Sell | 3.0K | $125.40 |
| 2026-06-10 | Mercier Johanna | Tax withheld | 1.3K | $121.48 |
| 2026-06-10 | Berger Dietmar | Option exercise | 533 | — |
| 2026-06-10 | Berger Dietmar | Tax withheld | 263 | $121.48 |
| 2026-06-10 | O'Day Daniel Patrick | Option exercise | 8.8K | — |
| 2026-06-10 | Dickinson Andrew D | Option exercise | 2.8K | — |
| 2026-06-10 | Dickinson Andrew D | Tax withheld | 1.3K | $121.48 |
| 2026-06-10 | O'Day Daniel Patrick | Tax withheld | 4.2K | $121.48 |
| 2026-06-10 | Cain Wettan Keeley M | Option exercise | 589 | — |
| 2026-06-10 | Cain Wettan Keeley M | Tax withheld | 283 | $121.48 |
| 2026-06-10 | Mercier Johanna | Option exercise | 2.8K | — |
| 2026-06-01 | O'Day Daniel Patrick | Sell | 11K | $131.10 |
| 2026-06-01 | O'Day Daniel Patrick | Sell | 3.1K | $132.22 |
| 2026-06-01 | O'Day Daniel Patrick | Sell | 1.0K | $132.97 |
| 2026-05-15 | Mercier Johanna | Option exercise | 25K | $66.64 |
| 2026-05-15 | Mercier Johanna | Sell | 7.7K | $130.29 |
| 2026-05-15 | Mercier Johanna | Sell | 11K | $131.19 |
| 2026-05-15 | Mercier Johanna | Sell | 8.4K | $132.23 |
| 2026-05-15 | Mercier Johanna | Sell | 700 | $132.75 |
| 2026-05-15 | Dickinson Andrew D | Sell | 3.0K | $132.27 |
| 2026-04-30 | Bluestone Jeffrey | Grant | 1.1K | — |
| 2026-04-30 | Horning Sandra | Grant | 1.1K | — |
| 2026-04-30 | MANWANI HARISH | Grant | 1.1K | — |
| 2026-04-30 | MANWANI HARISH | Tax withheld | 224 | $130.84 |
| 2026-04-30 | Rodriguez Javier | Grant | 1.1K | — |
| 2026-04-30 | WELTERS ANTHONY | Grant | 1.1K | — |
| 2026-04-30 | LOVE TED W | Grant | 1.1K | — |
| 2026-04-30 | BARTON JACQUELINE K | Grant | 1.1K | — |
| 2026-04-28 | O'Day Daniel Patrick | Sell | 7.0K | $128.79 |
| 2026-04-28 | O'Day Daniel Patrick | Sell | 3.0K | $130.01 |
| 2026-04-15 | Mercier Johanna | Sell | 3.0K | $140.96 |
| 2026-04-15 | Dickinson Andrew D | Sell | 3.0K | $140.96 |
| 2026-03-27 | O'Day Daniel Patrick | Sell | 10K | $136.82 |
| 2026-03-16 | Mercier Johanna | Sell | 3.0K | $144.23 |
| 2026-03-16 | Dickinson Andrew D | Sell | 3.0K | $144.23 |
| 2026-03-10 | Cain Wettan Keeley M | Option exercise | 1.2K | — |
| 2026-03-10 | Cain Wettan Keeley M | Tax withheld | 606 | $148.56 |
| 2026-03-10 | Mercier Johanna | Option exercise | 6.6K | — |
| 2026-03-10 | Mercier Johanna | Tax withheld | 3.2K | $148.56 |
| 2026-03-10 | Berger Dietmar | Option exercise | 2.1K | — |
| 2026-03-10 | Berger Dietmar | Tax withheld | 1.1K | $148.56 |
| 2026-03-10 | O'Day Daniel Patrick | Option exercise | 20K | — |
| 2026-03-10 | O'Day Daniel Patrick | Tax withheld | 9.8K | $148.56 |
| 2026-03-10 | Dickinson Andrew D | Option exercise | 6.5K | — |
| 2026-03-10 | Dickinson Andrew D | Tax withheld | 3.1K | $148.56 |
| 2026-02-27 | O'Day Daniel Patrick | Sell | 100 | $145.71 |
| 2026-02-27 | Cain Wettan Keeley M | Grant | 470 | — |
| 2026-02-27 | Mercier Johanna | Grant | 11K | — |
| 2026-02-27 | Berger Dietmar | Grant | 8.5K | — |
| 2026-02-27 | O'Day Daniel Patrick | Grant | 38K | — |
| 2026-02-27 | O'Day Daniel Patrick | Sell | 3.5K | $144.04 |
| 2026-02-27 | O'Day Daniel Patrick | Sell | 6.4K | $145.18 |
| 2026-02-27 | Dickinson Andrew D | Grant | 11K | — |
| 2026-02-17 | Mercier Johanna | Option exercise | 25K | $66.64 |
| 2026-02-17 | Mercier Johanna | Sell | 18K | $154.18 |
| 2026-02-17 | Mercier Johanna | Sell | 9.4K | $154.91 |
| 2026-02-17 | Mercier Johanna | Sell | 200 | $155.62 |
| 2026-02-17 | Dickinson Andrew D | Sell | 3.0K | $154.43 |
| 2026-02-05 | O'Day Daniel Patrick | Option exercise | 116K | $66.01 |
| 2026-02-05 | O'Day Daniel Patrick | Sell | 116K | $150.00 |
| 2026-02-03 | Mercier Johanna | Grant | 45K | — |
| 2026-02-03 | Mercier Johanna | Tax withheld | 25K | $143.28 |
| 2026-02-03 | O'Day Daniel Patrick | Grant | 132K | — |
| 2026-02-03 | O'Day Daniel Patrick | Tax withheld | 74K | $143.28 |
| 2026-02-03 | Dickinson Andrew D | Grant | 45K | — |
| 2026-02-03 | Dickinson Andrew D | Tax withheld | 25K | $143.28 |
| 2026-01-28 | O'Day Daniel Patrick | Sell | 5.0K | $139.54 |
| 2026-01-28 | O'Day Daniel Patrick | Sell | 5.0K | $140.24 |
| 2026-01-23 | O'Day Daniel Patrick | Option exercise | 116K | $66.01 |
| 2026-01-23 | O'Day Daniel Patrick | Sell | 116K | $135.00 |
| 2026-01-20 | Bluestone Jeffrey | Option exercise | 5.0K | $67.45 |
| 2026-01-20 | Bluestone Jeffrey | Sell | 5.0K | $123.50 |
| 2026-01-15 | Mercier Johanna | Sell | 3.0K | $124.31 |
| 2026-01-15 | Dickinson Andrew D | Sell | 3.0K | $124.31 |
| 2026-01-02 | Berger Dietmar | Option exercise | 16K | — |
| 2026-01-02 | Berger Dietmar | Tax withheld | 6.9K | $121.60 |
| 2025-12-29 | O'Day Daniel Patrick | Sell | 10K | $124.83 |
| 2025-12-15 | Mercier Johanna | Sell | 3.0K | $122.00 |
| 2025-12-15 | Dickinson Andrew D | Sell | 3.0K | $122.00 |
| 2025-12-10 | Mercier Johanna | Option exercise | 3.8K | — |
| 2025-12-10 | Mercier Johanna | Tax withheld | 1.8K | $121.34 |
| 2025-12-10 | O'Day Daniel Patrick | Option exercise | 10K | — |
| 2025-12-10 | O'Day Daniel Patrick | Tax withheld | 4.9K | $121.34 |
| 2025-12-10 | Dickinson Andrew D | Option exercise | 3.7K | — |
| 2025-12-10 | Dickinson Andrew D | Tax withheld | 1.7K | $121.34 |
| 2025-11-28 | Bluestone Jeffrey | Sell | 5.0K | $125.08 |
| 2025-11-28 | O'Day Daniel Patrick | Sell | 3.2K | $125.91 |
| 2025-11-28 | Bluestone Jeffrey | Option exercise | 5.0K | $64.92 |
| 2025-11-28 | O'Day Daniel Patrick | Sell | 6.8K | $126.84 |
| 2025-11-28 | Kramer Kelly A. | Option exercise | 2.8K | $81.00 |
| 2025-11-28 | Kramer Kelly A. | Sell | 2.8K | $127.10 |
| 2025-11-26 | Kramer Kelly A. | Option exercise | 2.8K | $81.00 |
| 2025-11-26 | Kramer Kelly A. | Sell | 2.8K | $127.11 |
| 2025-11-17 | Mercier Johanna | Sell | 2.5K | $126.26 |
| 2025-11-17 | Mercier Johanna | Option exercise | 25K | $66.64 |
| 2025-11-17 | Mercier Johanna | Sell | 26K | $125.83 |
| 2025-11-17 | Dickinson Andrew D | Sell | 2.5K | $125.23 |
| 2025-11-12 | Telman Deborah H | Option exercise | 17K | $75.12 |
| 2025-11-12 | Telman Deborah H | Sell | 17K | $124.00 |
| 2025-11-12 | Telman Deborah H | Option exercise | 36K | $60.75 |
| 2025-11-12 | Telman Deborah H | Sell | 36K | $122.30 |
| 2025-11-12 | Telman Deborah H | Option exercise | 500 | $60.75 |
| 2025-11-12 | Telman Deborah H | Sell | 500 | $122.90 |
| 2025-10-28 | O'Day Daniel Patrick | Sell | 8.0K | $119.54 |
| 2025-10-28 | O'Day Daniel Patrick | Sell | 2.0K | $118.82 |
| 2025-10-25 | Telman Deborah H | Tax withheld | 241 | $120.94 |
| 2025-10-25 | Telman Deborah H | Option exercise | 515 | — |
| 2025-10-15 | Dickinson Andrew D | Sell | 2.5K | $118.08 |
| 2025-10-15 | Mercier Johanna | Sell | 3.0K | $118.08 |
| 2025-09-29 | O'Day Daniel Patrick | Sell | 8.0K | $111.47 |
| 2025-09-29 | O'Day Daniel Patrick | Sell | 2.0K | $112.42 |
| 2025-09-15 | Mercier Johanna | Sell | 3.0K | $113.57 |
| 2025-09-15 | Dickinson Andrew D | Sell | 2.5K | $113.57 |
| 2025-09-10 | Telman Deborah H | Option exercise | 1.3K | — |
| 2025-09-10 | Telman Deborah H | Tax withheld | 634 | $115.25 |
| 2025-09-10 | Mercier Johanna | Option exercise | 3.8K | — |
| 2025-09-10 | Mercier Johanna | Tax withheld | 1.8K | $115.25 |
| 2025-09-10 | O'Day Daniel Patrick | Option exercise | 10K | — |
| 2025-09-10 | O'Day Daniel Patrick | Tax withheld | 4.9K | $115.25 |
| 2025-09-10 | Wilfong Diane E. | Option exercise | 921 | — |
| 2025-09-10 | Wilfong Diane E. | Tax withheld | 338 | $115.25 |
| 2025-09-10 | Dickinson Andrew D | Option exercise | 3.7K | — |
| 2025-09-10 | Dickinson Andrew D | Tax withheld | 1.8K | $115.25 |
| 2025-08-28 | O'Day Daniel Patrick | Sell | 10K | $113.63 |
| 2025-08-15 | Dickinson Andrew D | Sell | 2.5K | $118.53 |
| 2025-08-15 | Mercier Johanna | Option exercise | 12K | $66.64 |
| 2025-08-15 | Mercier Johanna | Sell | 12K | $118.50 |
| 2025-08-15 | Mercier Johanna | Option exercise | 700 | $66.64 |
| 2025-08-15 | Mercier Johanna | Sell | 700 | $118.97 |
| 2025-08-15 | Mercier Johanna | Option exercise | 12K | $66.64 |
| 2025-08-15 | Mercier Johanna | Sell | 12K | $118.51 |
| 2025-08-15 | Mercier Johanna | Option exercise | 700 | $66.64 |
| 2025-08-15 | Mercier Johanna | Sell | 700 | $118.97 |
| 2025-08-15 | Mercier Johanna | Sell | 2.8K | $118.51 |
| 2025-08-15 | Mercier Johanna | Sell | 200 | $118.97 |
| 2025-07-28 | O'Day Daniel Patrick | Sell | 1.7K | $113.17 |
| 2025-07-28 | O'Day Daniel Patrick | Sell | 8.3K | $114.09 |
| 2025-07-25 | Telman Deborah H | Option exercise | 514 | — |
| 2025-07-25 | Telman Deborah H | Option exercise | 8.2K | — |
| 2025-07-25 | Telman Deborah H | Tax withheld | 3.8K | $116.20 |
| 2025-07-15 | Mercier Johanna | Sell | 3.0K | $111.03 |
| 2025-07-15 | Dickinson Andrew D | Sell | 2.5K | $111.03 |
| 2025-07-14 | Bluestone Jeffrey | Option exercise | 5.0K | $67.45 |
| 2025-07-14 | Bluestone Jeffrey | Sell | 5.0K | $109.74 |
| 2025-06-30 | O'Day Daniel Patrick | Sell | 9.4K | $110.40 |
| 2025-06-30 | O'Day Daniel Patrick | Sell | 600 | $111.15 |
| 2025-06-16 | Dickinson Andrew D | Sell | 2.5K | $110.17 |
| 2025-06-16 | Mercier Johanna | Sell | 3.0K | $110.17 |
| 2025-06-10 | Wilfong Diane E. | Option exercise | 920 | — |
| 2025-06-10 | Wilfong Diane E. | Tax withheld | 340 | $110.09 |
| 2025-06-10 | Telman Deborah H | Option exercise | 1.3K | — |
| 2025-06-10 | Telman Deborah H | Tax withheld | 430 | $110.09 |
| 2025-06-10 | Mercier Johanna | Option exercise | 3.8K | — |
| 2025-06-10 | Mercier Johanna | Tax withheld | 1.8K | $110.09 |
| 2025-06-10 | O'Day Daniel Patrick | Option exercise | 10K | — |
| 2025-06-10 | O'Day Daniel Patrick | Tax withheld | 5.0K | $110.09 |
| 2025-06-10 | Dickinson Andrew D | Option exercise | 3.7K | — |
| 2025-06-10 | Dickinson Andrew D | Tax withheld | 1.8K | $110.09 |
| 2025-05-30 | O'Day Daniel Patrick | Sell | 6.4K | $110.11 |
| 2025-05-30 | O'Day Daniel Patrick | Sell | 3.6K | $110.96 |
| 2025-05-22 | Mercier Johanna | Sell | 12K | $107.52 |
| 2025-05-22 | Mercier Johanna | Option exercise | 12K | $66.64 |
| 2025-05-22 | Mercier Johanna | Option exercise | 12K | $66.64 |
| 2025-05-22 | Mercier Johanna | Sell | 12K | $107.52 |
| 2025-05-22 | Mercier Johanna | Sell | 3.0K | $107.52 |
| 2025-05-15 | Dickinson Andrew D | Sell | 2.5K | $99.82 |
| 2025-05-07 | WELTERS ANTHONY | Grant | 1.5K | — |
| 2025-05-07 | Rodriguez Javier | Grant | 1.5K | — |
| 2025-05-07 | LOVE TED W | Grant | 1.5K | — |
| 2025-05-07 | BARTON JACQUELINE K | Grant | 1.5K | — |
| 2025-05-07 | MANWANI HARISH | Tax withheld | 296 | $98.90 |
| 2025-05-07 | Horning Sandra | Grant | 1.5K | — |
| 2025-05-07 | MANWANI HARISH | Grant | 1.5K | — |
| 2025-04-25 | Telman Deborah H | Option exercise | 514 | — |
| 2025-04-25 | Telman Deborah H | Tax withheld | 158 | $103.17 |
| 2025-04-15 | Dickinson Andrew D | Sell | 2.5K | $106.40 |
| 2025-03-17 | Dickinson Andrew D | Sell | 2.5K | $110.53 |
| 2025-03-10 | Patterson Sandra | Option exercise | 2.0K | — |
| 2025-03-10 | Patterson Sandra | Tax withheld | 624 | $117.21 |
| 2025-03-10 | Dickinson Andrew D | Option exercise | 13K | $63.91 |
| 2025-03-10 | Mercier Johanna | Option exercise | 8.1K | — |
| 2025-03-10 | Mercier Johanna | Tax withheld | 3.9K | $117.21 |
| 2025-03-10 | O'Day Daniel Patrick | Option exercise | 24K | — |
| 2025-03-10 | O'Day Daniel Patrick | Tax withheld | 12K | $117.21 |
| 2025-03-10 | Telman Deborah H | Option exercise | 3.3K | — |
| 2025-03-10 | Telman Deborah H | Tax withheld | 1.1K | $117.21 |
| 2025-03-10 | Dickinson Andrew D | Option exercise | 4.9K | $63.91 |
| 2025-03-10 | Dickinson Andrew D | Sell | 4.9K | $117.30 |
| 2025-03-10 | Dickinson Andrew D | Sell | 13K | $118.50 |
| 2025-03-10 | Dickinson Andrew D | Option exercise | 8.0K | — |
| 2025-03-10 | Dickinson Andrew D | Tax withheld | 3.9K | $117.21 |
| 2025-02-18 | Dickinson Andrew D | Sell | 2.5K | $104.09 |
| 2025-02-18 | GILEAD SCIENCES, INC. | Buy | 1.4M | $11.00 |
| 2025-02-12 | Dickinson Andrew D | Option exercise | 26K | $57.92 |
| 2025-02-12 | Dickinson Andrew D | Option exercise | 16K | $80.72 |
| 2025-02-12 | Dickinson Andrew D | Option exercise | 18K | $83.49 |
| 2025-02-12 | Dickinson Andrew D | Sell | 138K | $102.22 |
| 2025-02-12 | Dickinson Andrew D | Option exercise | 78K | $63.91 |
| 2025-02-04 | Patterson Sandra | Grant | 709 | — |
| 2025-02-04 | O'Day Daniel Patrick | Grant | 60K | — |
| 2025-02-04 | O'Day Daniel Patrick | Grant | 164K | — |
| 2025-02-04 | O'Day Daniel Patrick | Tax withheld | 108K | $97.99 |
| 2025-02-04 | Mercier Johanna | Grant | 20K | — |
| 2025-02-04 | Mercier Johanna | Grant | 71K | — |
| 2025-02-04 | Mercier Johanna | Tax withheld | 46K | $97.99 |
| 2025-02-04 | Dickinson Andrew D | Grant | 20K | — |
| 2025-02-04 | Dickinson Andrew D | Grant | 65K | — |
| 2025-02-04 | Dickinson Andrew D | Tax withheld | 43K | $97.99 |
| 2025-02-04 | Telman Deborah H | Grant | 12K | — |
| 2025-01-31 | Dickinson Andrew D | Option exercise | 44K | $65.38 |
| 2025-01-31 | Dickinson Andrew D | Option exercise | 26K | $57.92 |
| 2025-01-31 | Dickinson Andrew D | Sell | 142K | $97.22 |
| 2025-01-31 | Dickinson Andrew D | Option exercise | 72K | $72.34 |
| 2025-01-25 | Telman Deborah H | Option exercise | 515 | — |
| 2025-01-25 | Telman Deborah H | Tax withheld | 187 | $93.07 |
| 2025-01-15 | Dickinson Andrew D | Sell | 2.5K | $91.35 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05633667 ↗ | Study of Novel Treatment Combinations in Patients With Lung Cancer Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer | PHASE2 | Active Not Recruiting | 2029-09-01 |
| NCT05502237 ↗ | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer Non-small Cell Lung Cancer | PHASE3 | Active Not Recruiting | 2028-06-01 |
| NCT05676931 ↗ | Study With Various Immunotherapy Treatments in Participants With Lung Cancer Advanced Non-Small Cell Lung Cancer | PHASE2 | Active Not Recruiting | 2027-12-01 |
| NCT05633654 ↗ | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Triple Negative Breast Cancer | PHASE3 | Recruiting | 2027-06-01 |
| NCT06727565 ↗ | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 Head and Neck Squamous Cell Carcinoma | PHASE2 | Active Not Recruiting | 2026-08-01 |
| NCT04891770 ↗ | Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) Chronic Hepatitis B | PHASE2 | Completed | 2024-01-23 |
| NCT03434353 ↗ | Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) Chronic Hepatitis B | PHASE2 | Terminated | 2020-01-20 |
| NCT01435044 ↗ | Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection Hepatitis C, Chronic | PHASE2 | Completed | 2013-04-01 |
| NCT00757237 ↗ | Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa Cystic Fibrosis | PHASE3 | Completed | 2010-05-01 |
| NCT00208299 ↗ | ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI) Coronary Artery Disease | PHASE3 | Completed | 2006-08-01 |
| NCT00208312 ↗ | ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI) Coronary Artery Disease | PHASE3 | Completed | 2005-06-01 |
| NCT01055847 ↗ | Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection Cystic Fibrosis, CF | PHASE2 | Completed | 2004-08-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (1)
Suppliers (3)
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-05-20 | Material agreementDebt obligationOtherExhibits | filing ↗ |
| 2026-05-07 | ResultsExhibits | filing ↗ |
| 2026-05-04 | Shareholder voteExhibits | filing ↗ |
| 2026-04-28 | Reg FDOtherExhibits | filing ↗ |
| 2026-02-23 | Material agreementReg FDExhibits | filing ↗ |
| 2026-02-10 | ResultsExhibits | filing ↗ |
| 2025-11-19 | Exec/director change | filing ↗ |
| 2025-10-30 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-20 | 2026-05-14 | 0001104659-26-064518 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0000882095-26-000024 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0000882095-26-000022 ↗ |
| 8-K | 2026-05-04 | 2026-04-30 | 0000882095-26-000008 ↗ |
| 8-K | 2026-04-28 | 2026-04-28 | 0001104659-26-049874 ↗ |
| 10-K | 2026-02-24 | 2025-12-31 | 0000882095-26-000006 ↗ |
| 8-K | 2026-02-23 | 2026-02-22 | 0001104659-26-018314 ↗ |
| 8-K | 2026-02-10 | 2026-02-10 | 0000882095-26-000003 ↗ |
| 8-K | 2025-11-19 | 2025-11-15 | 0001104659-25-113968 ↗ |
| 10-Q | 2025-11-07 | 2025-09-30 | 0000882095-25-000047 ↗ |
| 8-K | 2025-10-30 | 2025-10-30 | 0000882095-25-000044 ↗ |
| 8-K | 2025-10-06 | 2025-10-06 | 0000882095-25-000041 ↗ |